Test your recall of the most recent amendments to the heart failure guidelines on prevention, treatment of hypertension, and comorbidities.
Veronica Hackethal, MD
The HIJ-PROPER study found intensive LDL-lowering therapy added no additional therapeutic value in patients with ACS.
Results of this study suggest a role for the anti-inflammatory diet in secondary prevention.
A new study supports the utility of pulmonary arterial proportional pulse pressure to predict 5-year mortality in patients with PAH.
The AACE/ACE 2017 recommendations on lipid management prescribe LDL-C targets, and go far lower than any group has ventured to date.
While the strength of evidence for this "protective" effect is low, observers support further comparative effectiveness research in these patient groups.
Patients with comorbid T2D and heart failure may have a "distinct pathophysiology of the heart" say authors of a new study.
Findings from the REAL-CVD outcomes study reported at ACC.17 suggest class effect for cardioprotection.
Statins are clinically proven to improve CV outcomes--a new study offers insight into the mechanisms at work on arterial plaque.
A new analysis of qualitative studies points to poor communication on multiple levels.